Recent study shows that low-dose apatinib modulates the tumor immunosuppressive microenvironment and enhances the anti-tumor effect of anti-PD-L1 medicine, which delays tumor growth, reduces the number of metastases, and prolonged survival in mouse models (24). Here, CD274 is linked to neoplasm.